RE:ONCY pelareorep as a potential bispecific or ADC payload.ONCY has demonstrated that pelareorep is capable of remodeling the TME.
And we also found that poor infiltration of immune effector cells and complex immunosuppressive TME in solid tumors requires combination therapies consisting of multispecific antibodies with other immunomodulatory agents, for example, immune checkpoint blockers, personalized neoantigen vaccines, and oncolytic virus.
So the combination of an ADC or bispecific + pelareorep + CPI is the next logical step for a Big Pharma to take involving this type of combination therapy in the treatment of multiple cancers beyond orphan and rare cancers.
https://www.nature.com/articles/s41392-021-00868-x